Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gecacitinib + donafenib + PD-1 inhibitor
- Development stage
- Unknown
- Lead developer
- Tianjin Medical University Cancer Institute and Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Gecacitinib + donafenib + PD-1 inhibitor is a combination therapy regimen being evaluated for the treatment of unresectable hepatocellular carcinoma (HCC). The regimen consists of gecacitinib, a selective Janus kinase 1 (JAK1) inhibitor; donafenib, a deuterated multi-kinase inhibitor targeting VEGFR and Raf kinases; and an unspecified programmed cell death protein 1 (PD-1) inhibitor. This combination aims to overcome resistance to prior immunotherapy by simultaneously targeting tumor angiogenesis, intracellular signaling pathways, and the immune microenvironment. It is currently being studied in a Phase II clinical trial sponsored by Tianjin Medical University Cancer Institute and Hospital as a second-line immune rechallenge therapy for patients who have failed previous PD-1/PD-L1 inhibitor treatments.
- Brand names
- Zeponid
- Other names
- Gecacitinib Combined With Donafenib and PD-1 Inhibitor
02
Targets
TYK2 (Tyrosine kinase 2)JAK2 (Janus kinase 2)BRAF (B-Raf proto-oncogene, serine/threonine kinase)PDCD1 (Programmed cell death protein 1 receptor)VEGFR2 (Vascular endothelial growth factor receptor 2)RAF1 (c-Raf-1 (Y340D/Y341D))PDGFR (PDGFR family)JAK1 (Janus kinase 1)ACVR1 (Activin receptor type I)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)JAK3 (Janus kinase 3)
Beyond the preview
Go deeper on gecacitinib + donafenib + PD-1 inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gecacitinib + donafenib + PD-1 inhibitor.